AC Immune (ACIU) Invested Capital (2014 - 2025)

AC Immune (ACIU) has 12 years of Invested Capital data on file, last reported at $74.5 million in Q4 2025.

• Quarterly Invested Capital fell 50.71% year-over-year to $74.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $74.5 million (down 50.71% YoY) and the FY2025 annual result came in at $71.8 million, down 52.49% from the prior year.
• Invested Capital eased to $74.5 million in Q4 2025 per ACIU's latest filing, from $78.1 million in the prior quarter.
• Across five years, Invested Capital topped out at $229.4 billion in Q1 2021 and bottomed at $74.5 million in Q4 2025.
• The 5-year median for Invested Capital is $165.6 million (2023), against an average of $31.7 billion.
• The widest annual swing landed in 2021, when Invested Capital soared 83345.96%; it then slumped 99.9% in 2022.
• Tracing ACIU's Invested Capital over 5 years: stood at $275.1 million in 2021, then sank by 31.26% to $189.1 million in 2022, then climbed by 5.49% to $199.4 million in 2023, then declined by 24.19% to $151.2 million in 2024, then plunged by 50.71% to $74.5 million in 2025.
• Per Business Quant, the three latest ACIU Invested Capital figures stand at $74.5 million (Q4 2025), $78.1 million (Q3 2025), and $90.3 million (Q2 2025).

Peer Comparison